Stock Analiz

Phathom Pharmaceuticals, Inc. PHAT

Biotechnology: Pharmaceutical Preparations · IPO 2019 · data as of November 13, 2026

$6.06Market cap $493M
Open the interactive analysis →

Phathom Pharmaceuticals, Inc. (PHAT) is a healthcare company listed in the US with a market value of about $493M. In the twelve months to September 30, 2026 it had revenue of $275M and net income of -$83M, a net margin of -30.2%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is shareholder returns (0/5).

Key numbers: a 5-year average ROIC of -292%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 248% above the current price.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2019. It was profitable in 0 of the last 8 years in our data. Its share count rose by 86% over three years (dilution for shareholders). It spends 19% of revenue on research and development.

Score: 1.2 / 5

Value1/5
Future growth3/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year

Valuation

P/E (TTM)—
Forward P/E10.2
P/FCF—
P/S1.8
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-4.3%
Shareholder yield0.0%
Intrinsic value vs. price+248%

Growth and quality

Revenue growth (1 yr)216.9%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-10096.8%
ROIC (5-yr avg.)-292.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 8 years

Fiscal yearTTM20252024202320222021202020192018
Revenue$275M$175M$55M$682000$0————
Net income-$83M-$221M-$334M-$202M-$198M-$144M-$129M-$255M-$1M
Free cash flow-$21M-$167M-$267M-$139M-$148M-$149M-$71M-$37M—
EPS (diluted)$-1.01$-3.03$-5.29$-3.93$-5.05$-3.89$-3.88$-22.45$-0.21
Net margin-30.2%-126.4%-605.1%-29558.9%—————
ROIC———-199.4%-612.1%-65.3%-40.8%-33.4%-145.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 10 analysts is $20.05, 231% above the current price; targets range from $7.50 to $29.00; the consensus rating is “none”; expected EPS is $-0.05 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Phathom Pharmaceuticals stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 248% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Phathom Pharmaceuticals pay a dividend?

Not currently.

Is Phathom Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. Phathom Pharmaceuticals scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.